Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Data from clinical and preclinical studies indicate that immune dysregulation, specifically of
inflammatory processes, is associated with symptoms of major depressive disorder (MDD) …

Anhedonia is one of the core symptoms of major depressive disorder (MDD), which is often
inadequately treated by traditional antidepressants. The modern framework of anhedonia …

Highlights•Stress and depression are characterized by loss of synapses in prefrontal
cortex.•Rapid acting antidepressants increase synaptic contacts in prefrontal cortex.•NMDA …

The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that
can last from several days to more than a week in some patients. The molecular …

Chronic pain patients frequently develop and suffer from mental comorbidities such as
depressive mood, impaired cognition, and other significant constraints of daily life, which …

Low-dose ketamine, an open-channel N-methyl d-aspartate receptor (NMDAR) antagonist,
mediates rapid antidepressant effects in humans that are mimicked in preclinical rodent …

Ketamine, a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, produces
rapid and long-lasting antidepressant effects in major depressive disorder (MDD) patients.(2 …

Altered myelin structure and oligodendrocyte function have been shown to correlate with
cognitive and motor dysfunction and deficits in social behavior. We and others have …

Depression is caused by a change in neural activity resulting from an increase in glutamate
that drives excitatory neurons and may be responsible for the decline in the activity and …